Synthesis of cryptolepine analogues as potential bioreducible anticancer agents

Bioorganic and Medicinal Chemistry

Volumn 15, Issue 19, 2007, Pages 6353-6360

  Seville, Scott ^a   Phillips, Roger M ^a   Shnyder, Steven D ^a   Wright, Colin W ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

Cryptolepis sanguinolenta; Cytotoxicity; Nitrocryptolepine analogues; Nitroquinone oxidoreductase; NQO1; NQO2

Indexed keywords

2 FLUORO 7,9 DINITROCRYPTOLEPINE; 8 CHLORO 9 NITROCRYPTOLEPINE; ANTINEOPLASTIC AGENT; CRYPTOLEPINE DERIVATIVE; DIHYDRONICOTINAMIDE RIBOSIDE; NICOTINAMIDE; NITROQUINONE OXIDOREDUCTASE; OXIDOREDUCTASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; MOLECULAR MODEL;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYTOSOL; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDOLE ALKALOIDS; INHIBITORY CONCENTRATION 50; PRODRUGS; QUINOLINES; QUINONE REDUCTASES; STRUCTURE-ACTIVITY RELATIONSHIP;

CRYPTOLEPIS SANGUINOLENTA;

EID: 34547670409     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2007.06.062     Document Type: Article

References (17)

1. Boye, G. L.; Ampofo, O. In Proceedings of the First International Seminar on Cryptolepine, University of Science and Technology: Kumassi, Ghana. 1983, pp 37-41.
2. Wright C.W., Addae-Kyereme J., Breen A.G., Brown J.E., Cox M.F., Croft S.L., Gokcek Y., Kendrick H., Phillips R.M., and Pollet P.L. J. Med. Chem. 44 (2001) 3187
3. Wright C.W., Phillipson J.D., Awe S.O., Kirby G.C., Warhurst D.C., Quetin-Leclercq J., and Angenot L. Phytother. Res. 10 (1996) 361
4. Bierer D.E., Fort D.M., Mendez C.D., Luo J., Imbach P.A., Dubenko L.G., Jolad S.D., Gerber R.E., Litvak J., Lu Q., Zhang P.S., Reed M.J., Waldeck N., Bruening R.C., Noamesi B.K., Hector R.F., Carlson T.J., and King S.R. J. Med. Chem. 41 (1998) 894
5. Onyeibor O., Croft S.L., Dodson H.I., Feiz-Haddad M., Kendrick H., Millington N.J., Parapini S., Phillips R.M., Seville S., Shnyder S.D., Taramelli D., and Wright C.W. J. Med. Chem. 48 (2005) 2701
6. Ansah C., and Gooderham N.J. Toxicol. Sci. 70 (2002) 245
7. Lisgarten J.N., Coll M., Portugal J., Wright C.W., and Aymami J. Nat. Struct. Biol. 9 (2002) 57
8. Bonjean K., De Pauw-Gillet M.C., Defresne M.P., Colson P., Houssier C., Dassonneville L., Bailly C., Greimers R., Wright C., Quetin-Leclercq J., Tits M., and Angenot L. Biochemistry 37 (1998) 5136
9. Knox R.J., Burke P.J., Chen S., and Kerr D.J. Curr. Pharm. Design. 9 (2003) 2091
10. Knox R.J., Boland M.P., Friedlos F., Coles C., Southan C., and Roberts J.J. Biochem. Pharmacol. 37 (1988) 4671
11. Holt S.J., and Petrow V. J. Chem. Soc. (1947) 607
12. Phillips R.M. Biochem. Pharm. 52 (1996) 1711
13. Traver R.D., Horikoshi T., Danenberg K.D., Stadlbauer T.H.W., Danenberg P.V., Ross D., and Gibson N.W. Cancer Res. 52 (1992) 797
14. Cadenas E. Biochem. Pharm. 49 (1995) 127
15. Winski S.L., Faig M., Bianchet M.A., Siegel D., Swann E., Fung K., Duncan M.W., Moody C.J., Amzel L.M., and Ross D. Biochemistry 40 (2001) 15135
16. Mosmann T. J. Immunol. Methods 65 (1983) 55
17. Walton M.I., Smith P.J., and Workman P. Cancer Commun. 3 (1991) 199